When Japanese adults with type 2 diabetes take sitagliptin plus ipragliflozin for 24 weeks, their outer fat layer shrinks, but those taking metformin gain outer fat, with a clear difference between the two treatments.

Scientific Claim

In Japanese patients with type 2 diabetes treated with sitagliptin, 24 weeks of ipragliflozin (50 mg daily) decreases subcutaneous fat area by 7.03% while metformin (1000-1500 mg daily) increases it by 2.15%, resulting in a statistically significant difference of 9.18% (95% CI: -15.34 to -3.03; P=0.004).

Original Statement

“The reduction in subcutaneous fat area in the ipragliflozin group was significantly greater than in the metformin group (−7.03% vs. 2.15%, P = 0.004).”

From study:Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The study is a randomized controlled trial with appropriate controls, allowing definitive causal language for the measured outcomes within the study's population and duration.

Evidence from Studies

Supporting (1)

Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Randomized Controlled Trial

Human

2019 Aug

Contradicting (0)

No contradicting evidence found

Source Study

Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Score: 72

DOI: 10.1111/dom.13750

Similar Assertions

For Japanese adults with type 2 diabetes taking sitagliptin, taking ipragliflozin for 24 weeks makes belly fat inside the body decrease more than taking metformin, with a noticeable difference in fat loss.

96%

For Japanese adults with type 2 diabetes on sitagliptin, ipragliflozin lowers insulin levels significantly more than metformin, which actually slightly raises insulin levels, with a clear difference between the two treatments.

93%

For Japanese adults with type 2 diabetes on sitagliptin, metformin reduces bad cholesterol more than ipragliflozin, which actually raises bad cholesterol levels, with a clear difference between the two treatments.

87%

For Japanese adults with type 2 diabetes on sitagliptin, ipragliflozin reduces waist size more than metformin after 24 weeks, with a noticeable difference in how much waist circumference decreases.

87%

For Japanese adults with type 2 diabetes on sitagliptin, ipragliflozin boosts good cholesterol more than metformin after 24 weeks, with a noticeable difference in how much HDL levels rise.

86%